標(biāo)題: Titlebook: Novel Therapeutics from Modern Biotechnology; From Laboratory to H Dale L. Oxender,Leonard E. Post (Vice President, D Book 1999 Springer-Ve [打印本頁(yè)] 作者: 航天飛機(jī) 時(shí)間: 2025-3-21 16:29
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology影響因子(影響力)
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology被引頻次
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology被引頻次學(xué)科排名
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology年度引用
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology年度引用學(xué)科排名
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology讀者反饋
書(shū)目名稱(chēng)Novel Therapeutics from Modern Biotechnology讀者反饋學(xué)科排名
作者: parsimony 時(shí)間: 2025-3-21 23:40 作者: persistence 時(shí)間: 2025-3-22 00:32 作者: conservative 時(shí)間: 2025-3-22 07:30 作者: Clumsy 時(shí)間: 2025-3-22 12:48 作者: GEON 時(shí)間: 2025-3-22 13:42
SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytiult in death. Infants with underlying cardiac or pulmonary disease, and some premature/low-birth-weight infants are at considerably higher risk of more severe disease and increased mortality from RSV infection, and are candidates for prophylactic intervention during the winter months. Although not w作者: laxative 時(shí)間: 2025-3-22 19:33
Book 1999cal trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, suc作者: 路標(biāo) 時(shí)間: 2025-3-22 23:47 作者: 謊言 時(shí)間: 2025-3-23 01:53 作者: SLAG 時(shí)間: 2025-3-23 09:08 作者: Conjuction 時(shí)間: 2025-3-23 12:29
Preparation of Clinical Trial Supplies of Biopharmaceuticals,le time is available to optimize product gene expression or cell growth. Systems that are often employed include: 1) suspension culture in spinner vessels, roller bottles or other containers, 2) ascites production in mice, and 3) hollow-fiber bioreactors.作者: Calculus 時(shí)間: 2025-3-23 15:59 作者: 陳腐思想 時(shí)間: 2025-3-23 20:00
Novel Therapeutics from Modern Biotechnology978-3-642-59990-3Series ISSN 0171-2004 Series E-ISSN 1865-0325 作者: 撫育 時(shí)間: 2025-3-23 23:50
Handbook of Experimental Pharmacologyhttp://image.papertrans.cn/n/image/668468.jpg作者: 反叛者 時(shí)間: 2025-3-24 03:11 作者: ADOPT 時(shí)間: 2025-3-24 10:29 作者: 擦掉 時(shí)間: 2025-3-24 12:09
Preparation of Clinical Trial Supplies of Biopharmaceuticals,le time is available to optimize product gene expression or cell growth. Systems that are often employed include: 1) suspension culture in spinner vessels, roller bottles or other containers, 2) ascites production in mice, and 3) hollow-fiber bioreactors.作者: Suggestions 時(shí)間: 2025-3-24 15:43
Proteins as Drugs: Analysis, Formulation and Delivery,ever, the advent of recombinant DNA technology has resulted in a dramatic expansion of interest in their pharmaceutical applications. It now appears that we can make virtually any desired protein in sufficient quantities for therapeutic use, although often with significant difficulty. It is consider作者: 不能強(qiáng)迫我 時(shí)間: 2025-3-24 21:43
Strategies for Dealing With the Immunogenicity of Therapeutic Proteins,at their potential for use as therapeutics would be extremely high. However, the recognizable need for a defense system has implications for the administration of protein-based pharmaceuticals (Table 1). Minor differences in the primary structure of proteins—even as little as one amino acid from the作者: 運(yùn)動(dòng)的我 時(shí)間: 2025-3-25 01:55 作者: 季雨 時(shí)間: 2025-3-25 04:04
SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytif life. It is the dominant cause of severe lower respiratory-tract disease (bronchiolitis and pneumonia) in infants and young children, leading to approximately 100,000 hospitalizations each year in the United States alone (H. 1990). There are two major antigenically distinct subgroups of RSV, A and作者: insomnia 時(shí)間: 2025-3-25 08:46 作者: Bph773 時(shí)間: 2025-3-25 14:44 作者: sinoatrial-node 時(shí)間: 2025-3-25 18:43
Safe, Efficient Production of Retroviral Vectors,ene marking. Lymphocytes were removed from a melanoma biopsy, expanded in vitro and transduced with a retroviral vector carrying a gene that conferred resistance to the neomycin analogue, G-418. The clinical objective was to determine the distribution and longevity of these marked lymphocytes. Short作者: 大量 時(shí)間: 2025-3-25 22:47 作者: 傳授知識(shí) 時(shí)間: 2025-3-26 02:47 作者: grenade 時(shí)間: 2025-3-26 06:39 作者: hysterectomy 時(shí)間: 2025-3-26 12:28
Strategies for Dealing With the Immunogenicity of Therapeutic Proteins,istration of protein-based pharmaceuticals (Table 1). Minor differences in the primary structure of proteins—even as little as one amino acid from the human form of the protein—have been shown to be sufficient for immune system recognition.作者: osteocytes 時(shí)間: 2025-3-26 15:41
0171-2004 supplementary material: A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These anno作者: 上流社會(huì) 時(shí)間: 2025-3-26 19:44 作者: 大雨 時(shí)間: 2025-3-27 00:19
Safe, Efficient Production of Retroviral Vectors,d with the retroviral vector (LASN) that contained the wild-type ADA gene. Results of this and a related ADA trial, which involved the introduction of the gene into CD34. cells from umbilical-cord blood obtained from neonates, have been published (B. et al. 1995; K. et al. 1995).作者: remission 時(shí)間: 2025-3-27 05:03
Clinical Systems for the Production of Cells and Tissues for Human Therapy,Second, transplantation procedures continue to be cost prohibitive for otherwise medically warranted applications. Third, the procurement of suitable tissues is often prohibitively invasive for the donor, in many cases requiring cadaveric material to be used. As a result, the full potential of transplantation therapies has not yet been realized.作者: Cholesterol 時(shí)間: 2025-3-27 09:18
Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials, referred to as the “case-by-case” approach. A combination of early dialogue, to identify the critical questions unique to an emerging technology, and a science-based rational approach, to answer these questions, has resulted not only in facilitation of clinical development, but in providing the appropriate data to support marketing applications.作者: 碎石頭 時(shí)間: 2025-3-27 09:53 作者: 滲透 時(shí)間: 2025-3-27 15:37
Formulation and Delivery of Nucleic Acids,ly into the affected tissues in vivo. One of the major challenges for the direct gene-transfer approach is to develop a vehicle that is able to protect the nucleic acids from degradation, while delivering the genes of interest to specific tissues and target-cell compartments.作者: 植物群 時(shí)間: 2025-3-27 21:13
Book 1999 "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the "New Biology". . At the t作者: Perennial長(zhǎng)期的 時(shí)間: 2025-3-28 00:43
8樓作者: Acquired 時(shí)間: 2025-3-28 03:39
8樓作者: Antecedent 時(shí)間: 2025-3-28 06:54
8樓作者: 發(fā)酵 時(shí)間: 2025-3-28 11:22
9樓作者: anthropologist 時(shí)間: 2025-3-28 18:29
9樓作者: 空氣傳播 時(shí)間: 2025-3-28 19:36
9樓作者: Fillet,Filet 時(shí)間: 2025-3-29 02:48
9樓作者: 橫條 時(shí)間: 2025-3-29 03:51
10樓作者: creditor 時(shí)間: 2025-3-29 07:25
10樓作者: 茁壯成長(zhǎng) 時(shí)間: 2025-3-29 13:09
10樓作者: archaeology 時(shí)間: 2025-3-29 17:32
10樓
